Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Clinical Trial
[키워드] ACE-2
Adaptive immunity
AIDS/HIV
Antiretroviral therapy
AZD1222
baseline
Beta coronaviruses
CD4
Cell-mediated immunity
Cellular immune response
ChAdOx1 nCoV-19
Cohort
correlated
COVID-19
cross-reactive
detectable
dose
Duration
Evidence
greater
HIV
HIV-uninfected
humoral
IFN-γ ELISPOT
IgG ELISA
immune response
Immunity
individual
majority
male participant
marker
Meso Scale Discovery
neutralization
no significant difference
prevaccination
regimen
response
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 spike
serology
Support
T cell
T cell proliferation
T cell response
T cells
Trial
undetectable
vaccinate
vaccination
variants of concern
viral loads
with HIV
[DOI] 10.1172/jci.insight.157031 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1172/jci.insight.157031 PMC 바로가기 [Article Type] Clinical Trial